22 November 2017
News and Views
Links and Services
Concomitant immunomodulators do not improve efficacy or pharmacokinetics in IBD patients who receive maintenance infliximab, finds a study in Alimentary Pharmacology and Therapeutics.
The benefits and risks of concomitant immunomodulators and maintenance infliximab in inflammatory
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors